Maria Pia Morelli
Overview
Explore the profile of Maria Pia Morelli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
317
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yousef M, Yousef A, Chowdhury S, Fanaeian M, Knafl M, Peterson J, et al.
JAMA Oncol
. 2024 Sep;
10(11):1519-1529.
PMID: 39264607
Importance: Disparity in overall survival (OS) and differences in the frequency of driver gene variants by race and ethnicity have been separately observed in patients with colorectal cancer; however, how...
2.
Hecht J, Mitchell J, Morelli M, Anandappa G, Yang J
Am Soc Clin Oncol Educ Book
. 2023 Jun;
43:e389072.
PMID: 37290032
Immunotherapy has only had a modest impact on the treatment of advanced GI malignancies. Microsatellite-stable colorectal cancer and pancreatic adenocarcinoma, the most common GI tumors, have not benefited from treatment...
3.
Cole C, Morelli M, Fantini M, Miettinen M, Fetsch P, Peer C, et al.
J Exp Clin Cancer Res
. 2023 Apr;
42(1):102.
PMID: 37101182
No abstract available.
4.
Cole C, Morelli M, Fantini M, Miettinen M, Fetsch P, Peer C, et al.
J Exp Clin Cancer Res
. 2023 Mar;
42(1):76.
PMID: 36991390
Background: NEO201 is a humanized IgG1 monoclonal antibody (mAb) generated against tumor-associated antigens from patients with colorectal cancer. NEO-201 binds to core 1 or extended core 1 O-glycans expressed by...
5.
Zeineddine F, Zeineddine M, Yousef A, Gu Y, Chowdhury S, Dasari A, et al.
NPJ Precis Oncol
. 2023 Feb;
7(1):16.
PMID: 36781990
Over the past two decades of successive clinical trials in metastatic colorectal cancer (CRC), the median overall survival of both control and experimental arms has steadily improved. However, the incremental...
6.
Tsang K, Fantini M, Zaki A, Mavroukakis S, Morelli M, Annunziata C, et al.
Cancers (Basel)
. 2022 Oct;
14(20).
PMID: 36291783
Truncated O-glycans expressed in cancer cells support tumor progression, and they may serve as potential targets to improve the monitoring and treatment of cancers. Previously, we reported that NEO-201 binds...
7.
Michailidou D, Khaki A, Morelli M, Diamantopoulos L, Singh N, Grivas P
Sci Rep
. 2021 Apr;
11(1):9029.
PMID: 33907229
Patients with cancer treated with immune checkpoint inhibitors (ICIs) develop immune related adverse events (irAEs), however biomarkers are lacking. We hypothesized that clinicopathologic and laboratory factors would be associated with...
8.
Zeligs K, Morelli M, David J, Neuman M, Hernandez L, Hewitt S, et al.
Front Oncol
. 2020 Jul;
10:805.
PMID: 32637350
Despite high initial response rates with cytoreductive surgery, conventional chemotherapy and the incorporation of biologic agents, ovarian cancer patients often relapse and die from their disease. New approaches are needed...
9.
Fantini M, David J, Annunziata C, Morelli M, Arlen P, Tsang K
Cancer Biother Radiopharm
. 2020 Jan;
35(3):190-198.
PMID: 31928422
Natural killer (NK) cells are essential to innate immunity and participate in cancer immune surveillance. Heterophilic interactions between carcinoembryonic antigen (CEA) on tumor cells and carcinoembryonic antigen-related cell adhesion molecule...
10.
Arlen P, Morelli M
Expert Opin Biol Ther
. 2019 Nov;
20(2):105-108.
PMID: 31755317
No abstract available.